Enstilar with Enbrel or Humira for Plaque Psoriasis

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Recruiting Phase 4 Interventional Study
Psoriasis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
30 (estimated)
Sponsor
Psoriasis Treatment Center of Central New Jersey · Other
Who this trial is looking for

This trial is looking for adults aged 18 or older who have chronic plaque psoriasis. Participants must have a specific level of skin involvement and have been on certain treatments for at least 24 weeks.

Are You a Good Fit for This Trial?
Must be taking EnbrelHumira

You may be able to join if

  • I am 18 years old or older
  • I have chronic plaque-type psoriasis
  • I have 2-10% body surface area affected
  • My Physician Global Assessment score is 2 or greater
  • I have been treated with Enbrel or Humira for at least 24 weeks

You may not be able to join if

  • I have less than 2% or more than 10% body surface area affected
  • My Physician Global Assessment score is less than 2
  • I am not receiving Enbrel or Humira
  • I have been receiving Enbrel or Humira for less than 24 weeks

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Male or female adult ≥ 18 years of age; * Diagnosis of chronic plaque-type * Patient with 2-10% BSA * Physician Global Assessment of 2 or greater * Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks Exclusion Criteria: * ˂2 or \>10% BSA * PGA \<…
Contacts

Jerry Bagel, MD

6094434500

dreamacres1@aol.com

CONTACT

Elise Nelson

6094434500

enelson@windsordermatology.com

CONTACT